Long-term study confirms Vioxx heart risks
A research study to recruit foreign language speaking cancer patients through Australian Cancer Registries will begin in New South Wales this month. The study aims to assess anxiety, depression and quality of life in Greek, Chinese and Arabic speaking cancer patients in Australia. It will also document unmet needs and patterns of care throughout their
Full Post: Cancer study a world first
By Julie Steenhuysen
CHICAGO (Reuters) - A long-term analysis of people who took the arthritis drug Vioxx confirms it doubles the risk of strokes and heart attacks, researchers said on Monday, but this risk goes away a year after people stop taking it.
And other drugs in the same class of painkillers known as Cox-2 inhibitors may cause similar harm, they said.
“The good news is the data suggests that the risk doesn’t persist forever. The risk goes back toward normal after a year of follow up,” said Dr. Robert Bresalier of the M.D. Anderson Cancer Center at the University of Texas, whose study appears in the journal Lancet.
Safety data from this same study in 2004 set off alarms that Vioxx increased the risks of heart attacks and stroke, prompting drug maker Merck & Co Inc to withdraw the popular painkiller from the market.
Merck last year inked a $4.85 billion deal to settle thousands of claims for heart attacks, strokes and deaths allegedly caused by the drug. The original study, funded by Merck, was meant to determine whether Vioxx could prevent polyps that raise the risk of colon cancer.
A 2005 analysis by Bresalier and colleagues published in the New England Journal of Medicine suggested that it took 18 months for the drug to increase the risk of heart attacks and strokes, a time frame that played a prominent role in Merck’s legal defense of Vioxx.
The journal later posted a correction on its Web site, saying the difference was not statistically significant. The new analysis, done with independent statisticians, suggests the risk occurs early and persists, Bresalier said.
“This data shows you can’t precisely determine the timing of the risk. It does appear to start relatively early,” he said in a telephone interview. Continued…
--------------------------------------------------------------------------------------------Related Posts:
WASHINGTON - Women who take hormone replacement therapy to treat menopause symptoms do not have a higher than usual risk of heart attack, especially if they use a cream or skin patch or take cyclic hormone combinations, Danish researchers reported yesterday. Their study, published in the European Heart Journal, suggests it is not hormone replacement therapy
Full Post: Study finds HRT does not increase heart attack risk
--------------------------------------------------------------------------------------------
Thursday October 16, 2008 (foodconsumer.org) — In the National Breast Cancer Awareness Month, you may do something to help yourselves reduce the risk of breast cancer. But first, equip yourselves with current knowledge about how to prevent the disease. We have published quite a few articles on breast cancer prevention because it is better
Full Post: Radiotherapy raises risk of contralateral breast cancer - Study
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Data from the Women’s Health Initiative Observational Study show that higher than normal insulin levels are an independent risk factor for breast cancer. Study investigators, led by Dr. Marc J. Gunter at Albert Einstein College of Medicine in the Bronx, New York, examined the association between breast cancer and blood parameters
Full Post: High insulin levels may increase breast cancer risk
--------------------------------------------------------------------------------------------
Testosterone, the male sex hormone, boosts sexual desire and activities in postmenopausal women, according to a recent study. But a small review published earlier said the effect of the male hormone therapy on the risk of breast cancer remains uncertain. Off-label use of testosterone is allowed in the United States although the FDA has
Full Post: Testosterone patch drives women crazy in bedroom, but cancer risk uncertain
--------------------------------------------------------------------------------------------
Breast cancer patients are risking their lives by failing to take the tamoxifen they are prescribed, according to a new study published in the British Journal of Cancer.Half of the women failed to finish a five year course of the drug and one in five regularly forget to take a tablet.Experts already know that taking
Full Post: Women risk their lives by failing to take breast cancer drugs